fda compounding semaglutide warning letters september 2025 Beyond the Headlines: to GLP-1 Compounders The FDA sent a warning

RESTRICCIONES: Este producto no es un medicamento, no exceder la porcin recomendada, no se use en embarazo, lactancia o padecimientos crnicos sin consultar a un mdico, mantngase fuera del alcance de los nios

It wasnt about looksit just helped my body feel more balanced. Daniel Smith, Seattle, Washington, United States I started noticing the skin on my arms getting loose and kind of deflatedit felt off, like my body was slipping out of balance

On August 27, 2025, the FDA approved the first generic version of liraglutide (Saxenda) for weight loss in adults and adolescents with obesity and adults with overweight and at least one weight-related comorbid condition

Ingels M, Beauchamp J, Clark RF, Williams SR: Delayed valproic acid toxicity: a retrospective case series

By the time we reach our 40s and 50s, the gap between what we produce and what we need can become significant